

Damage goes beyond VOCs.
Hemolysis is silently causing:
Kyle
Living With Sickle Cell
References:
1. Xue J, Li XA. Therapeutics for sickle cell disease intravascular hemolysis. Front Physiol. 2024;15:1474569. doi:10.3389/fphys.2024.1474569 2. Xu JZ, Thein SL. Revisiting anemia in sickle cell disease and finding the balance with therapeutic approaches. Blood. 2022;139(20):3030-3039. doi:10.1182/blood.2021013873 3. Ballas SK, Kuypers FA, Gordeuk VR, Hankins JS, Thompson AA, Vichinsky E. Time to rethink haemoglobin threshold guidelines in sickle cell disease. Br J Haematol. 2021;195(4):518-522. doi:10.1111/bjh.17578 4. Kato GJ, Steinberg MH, Gladwin MT. Intravascular hemolysis and the pathophysiology of sickle cell disease. J Clin Invest. 2017;127(3):750-760. doi:10.1172/JCI89741 5. Ataga KI, Gordeuk VR, Agodoa I, Colby JA, Gittings K, Allen IE. Low hemoglobin increases risk for cerebrovascular disease, kidney disease, pulmonary vasculopathy, and mortality in sickle cell disease: a systematic literature review and meta-analysis. PLoS One. 2020;15(4):e0229959. doi:10.1371/journal.pone.0229959